Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | EGFR806CAR(2G)-EGFRt |
| Trade Name | |
| Synonyms | autologous CD4+/CD8+ T cells expressing EGFR806-specific CAR/EGFRt |
| Drug Descriptions |
EGFR806CAR(2G)-EGFRt comprises CD4+ and CD8+ T-lymphocytes engineered to express a chimeric antigen receptor (CAR) composed of a depatuxizumab-derived binding domain, which targets EGFR linked to the intracellular domain of TNFRSF9 (4-1BB), CD3zeta, and a truncated form of EGFR, which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing EGFR (NCI Drug Dictionary, J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9116). |
| DrugClasses | EGFR Immune Cell Therapy 5 |
| CAS Registry Number | NA |
| NCIT ID | C156883 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CD19CAR(2G)-T2A-HER2tG + EGFR806CAR(2G)-EGFRt | CD19CAR(2G)-T2A-HER2tG EGFR806CAR(2G)-EGFRt | 0 | 1 |
| EGFR806CAR(2G)-EGFRt | EGFR806CAR(2G)-EGFRt | 0 | 2 |